Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec) are expressed in non-leukemic hematopoietic cells...

Full description

Bibliographic Details
Main Authors: Leigh Naylor-Adamson, Anisha R. Chacko, Zoe Booth, Stefano Caserta, Jenna Jarvis, Sujoy Khan, Simon P. Hart, Francisco Rivero, David J. Allsup, Mònica Arman
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
platelet
FcγRIIA
Staphylococcus aureus
Escherichia coli
Bruton’s tyrosine kinase inhibitor
ibrutinib
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.766272/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.766272/full

Similar Items